SA
Go ProLog In
NGNE
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
6 analysts·Limited coverage
71
Score
5 Buy (83%)1 Hold (17%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
583%
Hold
117%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$69.00
+156.7%
Consensus
$69.00
+156.7%
Bull
$69.00
+156.7%
12-Month Target Range6 analysts
$69.00$69.00$69.00
Current $26.88Consensus
Current Price
$26.88
Upside to Consensus
$42.12

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev—
EPS—
FY2028
Rev—
EPS—
FY2029
Rev+107.13%
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 28, 2026Guggenheim
Neurogene initiated with a Buy at Guggenheim
Target:$69.00
+155.1%from $27.05
Oct 2, 2025H.C. Wainwright
Neurogene looks 'deeply undervalued' after Taysha news, says H.C. Wainwright
Target:$45.00
+118.3%from $20.61
Apr 14, 2025BMO Capital
Neurogene price target lowered to $16 from $45 at BMO Capital
Target:$16.00
+46.9%from $10.89
Mar 25, 2025Robert W. Baird
Neurogene price target lowered to $38 from $46 at Baird
Target:$38.00
+167.6%from $14.20
Mar 25, 2025H.C. Wainwright
Neurogene price target lowered to $50 from $55 at H.C. Wainwright
Target:$50.00
+252.1%from $14.20
Nov 20, 2024Stifel Nicolaus
Neurogene (NGNE) PT Lowered to $46 at Stifel
Target:$46.00
+200.1%from $15.33
Nov 19, 2024BMO Capital
Neurogene (NGNE) PT Lowered to $45 at BMO Capital
Target:$45.00
+26.4%from $35.59
Nov 12, 2024BMO Capital
Neurogene (NGNE) PT Lowered to $60 at BMO Capital
Target:$60.00
-6.9%from $64.48
Nov 12, 2024Stifel Nicolaus
Neurogene (NGNE) PT Raised to $60 at Stifel
Target:$60.00
-6.9%from $64.48
Aug 12, 2024H.C. Wainwright
Neurogene price target lowered to $49 from $51 at H.C. Wainwright
Target:$49.00
+37.7%from $35.59
Jun 26, 2024BMO Capital
BMO Capital Starts Neurogene (NGNE) at Outperform
Target:$65.00
+103.1%from $32.01
Jun 10, 2024Robert W. Baird
Baird Starts Neurogene (NGNE) at Outperform
Target:$54.00
+44.6%from $37.35
May 13, 2024H.C. Wainwright
Neurogene (NGNE) PT Lowered to $51 at H.C. Wainwright
Target:$51.00
+68.5%from $30.26

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance